Trade Ideas Flow (@TradeIdeasFlow) header
Trade Ideas Flow (@TradeIdeasFlow) profile picture

Ex-Equity PM & Quant. I built an AI engine to apply 10y+ institutional rigor to the open web. 🟒 Scanning for hidden gems. πŸ’Ž I invest my capital using this.

Tracking 1,000+ Authors
Joined December 2025
Photo by Trade Ideas Flow (@TradeIdeasFlow)Photo by Trade Ideas Flow (@TradeIdeasFlow)Photo by Trade Ideas Flow (@TradeIdeasFlow)Photo by Trade Ideas Flow (@TradeIdeasFlow)Photo by Trade Ideas Flow (@TradeIdeasFlow)Photo by Trade Ideas Flow (@TradeIdeasFlow)Photo by Trade Ideas Flow (@TradeIdeasFlow)Photo by Trade Ideas Flow (@TradeIdeasFlow)Photo by Trade Ideas Flow (@TradeIdeasFlow)Photo by Trade Ideas Flow (@TradeIdeasFlow)
πŸ“Š H1 2026 is in the books - our first real out-of-sample stretch. The setup: we built Trade Ideas Flow in late 2025, then froze everything - definitions, methods, hyperparameters, prompts. No tuning. No hindsight. Just the system running daily. The result: 🟒 TIF: +18% βšͺ S&P 500: +9% πŸ’Ž +9% alpha in 6 months Every pick was published to the web + emailed to subscribers in real time. The audit trail speaks for itself. Not advice. Just how we run the process. Past performance β‰  future results. Link below if you want to see how it keeps performing and want to get our picks (FREE for now)
4
7
1,377
Most interesting thing I read this week is about phone software for small businesses. $CXDO pitched by @sammccolgan Crexendo. Around 250 local telecom and IT providers rent its platform and sell phone service under their own brand, "much as an online shop runs on Shopify without its customers knowing". Over 8 million people make work calls on it, most never heard the name. Stock has halved since June and closed Friday at $4.92. Every bear Sam talks to says the same thing, software growth is slowing. And licence sales did fall 25% in the first 9 months. Licences are the lumpy part though, capacity bought upfront in blocks, and new customers now start with smaller orders and top up as they move users across. The recurring line underneath grows 16 to 20% a year. Hold licences flat and software growth is back to about 13% in 2027 by Sam's maths. For proof Sam went to BroadSoft, the incumbent in this exact market until Cisco bought it in 2018, which reported the same 2 lines for a decade. Its licence growth swung from -5% to +70%, back to roughly zero, up to 24%, down to -3%. Recurring line grew every quarter. "The market is busy counting Crexendo's licence sales. I think it is missing the gorilla." THE GORILLA Management dropped pieces of it on calls and at conferences: what the AI receptionist earns per account, how many licensees resell it, a price range for call analysis, how fast the app store grows. "I have yet to see anyone put the pieces together." Sam did, and counts 5 income streams. The number that matters. Crexendo makes about $80 a year from each business on a licensee's platform, and there are about 390,000 of them. CAIRO, the AI receptionist, earns it about $900 a year from each business that takes it. THE NUMBERS β†’ EBITDA (roughly cash profit before interest and tax) about $15M this year β†’ Sam's base case: about $54M in 2028, about $40M if AI take-up is half the assumption β†’ Analysts: $21M β†’ Enterprise value about $150M at the $5.07 it was written at, so the price pays for almost none of it THE DEALS Spare cash goes into buying its own licensees at about 1.3x revenue. Same platform, so no migration risk. ESI cost about 10x EBITDA, about 8.4x after savings, and about 5.5x once Crexendo sells the AI add-ons to the customers it bought. A year from now Sam values it at about $6.40 with no AI and no deals, $8.10 with the deals, $18 to $24 with the AI streams. First real test is year-end results, when management gives CAIRO numbers for the first time. Sam and the fund are long. "If I'm wrong, I own a growing, cash-generative business near its historical lows. If I'm even half right on AI, the shares are worth several times today's price."
1
177
Sam's full write-up, with all 5 AI streams modelled line by line and every assumption on the page to poke holes in: πŸ“– cadoccapital.substack.com/p/… I read every pitch like this at tradeideasflow.ai πŸ’ŽπŸŸ’
42
563 stock pitches were published last week. I read them and 4 made the issue. πŸ’Ž Weekly Stock GEMs #21 is out. Sun Kwang, ASA International, Galaxy Gaming and Northern Bear. Korea's grain docks right after the family finished paying its gift tax, a microlender losing less than US credit cards, blackjack side bets at half what a buyer agreed to pay, and UK roofers profitable 18 years running.
1
1
116
5 more I read and liked, all credited inside the issue. πŸ”Ή DIT Corp: SK hynix's laser annealing supplier at 5.5x earnings, priced mostly at its net cash, with a larger dividend due in February 2027. @NateValuetw πŸ”Ή TNE Korea ($0053F0.KQ): one of 2 qualified suppliers to Bloom Energy's fuel cells, at 9.6x earnings against MTAR and Kaori at 36 to 41x. @AC__research πŸ”Ή Volaris ($VLRS): an airline at 4.5x EBITDAR after 7 years of shocks, merging with Viva to enforce capacity discipline. @banyanlanecap πŸ”Ή Innovative Aerosystems: an aerospace manufacturer buying its way into sole-source, recurring aftermarket revenue, at 13 to 14x EBITDA. @LDiscernment πŸ”Ή James Cropper ($CRPR.L): a historic manufacturer turning around fast under a new management team, with possible FTSE AIM 100 entry at the December reshuffle. @RebelHQ All 9 authors did the research and I only chose between them, so follow them ahead of me. Link in the comments.
1
99
Inside: why Galaxy Gaming trades at $1.60 after Evolution agreed to pay $3.20, and the $33M of debt due January 2028 the write-up weighs against it. tradeideasflow.substack.com/…
32
πŸ’Ž MY FAVORITE STOCK PITCH THIS WEEKEND $003100.KQ, written up by @calvinblissett In 2004 Buffett went through a manual of Korean companies one Sunday afternoon and found Daehan Flour Mills at about 2x earnings. He bought around 38,000 won. Less than 2 years later it was 155,000. Calvin thinks Sun Kwang is another one, and it handles the same grain. Before wheat and corn get to a Korean flour or feed mill, they come off a ship. Sun Kwang runs the silos and docks that now take roughly 38% of Korea's grain imports, up from roughly a quarter a decade ago. Plus one of the 2 big container terminals at Incheon New Port, the port for greater Seoul. "You can put off a new car or a new phone. You can't put off dinner." THE PRICE β†’ β‚©18,800 a share, β‚©118B market cap β†’ 2.6x owner's earnings, so you pay β‚©2.6 for every β‚©1 the business makes in a year β†’ ~β‚©241B of cash, land and stakes in 12 port, ferry and logistics companies, none of it the terminals So half of what the side assets are worth buys the whole company, terminals included. In Calvin's words, "The market is paying you to take the docks." WHY IT STAYED CHEAP The family was handing shares down to the next generation. Korean gift tax values listed shares at the average price from 2 months before to 2 months after the gift, so every won the stock went up was more tax and the family had every reason to keep it quiet. Daily trading fell from β‚©1.78B in May to β‚©150M in September. Last gift was Sep 9, last tax window closed around Nov 9. Now heirs own shares directly and collect any dividend. Payout today is 7% of profit, at 40% it would be about β‚©2,400 a share, 12.8% on this price. THE FINE PRINT Calvin compared the dividend policy section year by year. FY2024 report: "The company has no plans to buy back or cancel treasury shares." FY2025 report, filed May 2026: that sentence is gone, rest reads the same. Nobody announced it. Calvin reads it as the step before cancelling the remaining 4.7% of treasury shares. Q3 report is due by Monday. Calvin owns it, about 10% of the portfolio, and the sum of parts at fair infrastructure multiples gets the equity to roughly β‚©600B, about 5x the market cap. "At this price, even a mediocre outcome is a good one."
1
1
3
650
Calvin's full write-up, with every number linked to its filing and the grain tonnage reverse-engineered terminal by terminal out of an academic study: πŸ“– nobrainerinvestments.substac… I read every pitch like this at tradeideasflow.ai πŸ’ŽπŸŸ’
64
πŸ’Ž A CATARACT LENS COMPANY PRICED UNDER ITS CASH $RXST pitched by @RusslanRamdowar RxSight makes a lens for cataract surgery that the doctor can still adjust after the eye heals, using the company's own light-delivery device in the clinic. Technology is already in clinics. Problem is demand. Q3, reported November 3: β†’ revenue $24.59M, down 19% β†’ lenses 23,128, down 11.2% β†’ installed light devices up to 1,170 from 1,109 β†’ gross margin 73.6%, against 79.9% a year earlier β†’ net loss $16.22M, from $9.82M Then the balance sheet. $254.68M of cash and short-term investments, and no bank borrowing reported. At the write-up's $4.54 the whole company was worth $190.35M on 41.9M shares, less than the cash. The Alcon deal, read out of the 10-Q. Alcon paid $60M in Q3 and it sits inside that $254.68M. $50M of it stopped being refundable on October 28. The $200M headline already counts the $60M, the other $140M is conditional milestones, and the 30% royalty is on collaboration products only. Ramdowar also does the subtraction: take the $60M out and 9 months of operations used $35.21M of cash. It closed Thursday at $5.38, up 18.5% since the write-up. Market cap there is about $226M (my math), still under the cash. The weighted model path in the write-up is $7.06 by September 2027 and $16.79 by September 2031, rated Strong Buy at both dates. What it needs is lens demand per installed device recovering enough to carry the cost base, and management gives 2027 guidance again with Q4 results.
1
133
Full write-up, with the Q3 cash bridge and all 20 quarterly checkpoints of the model: πŸ“– ipulseai.substack.com/p/ep-4… I read every pitch like this at tradeideasflow.ai πŸ’ŽπŸŸ’
73
538 stock pitches went out in the week to 5 November. 3 made this issue. πŸ“ˆ Thursday Tailwinds #14 is out. A recording head, a steel pole and a Japanese warehouse. A tailwind is a force that keeps pushing money toward the same companies for as long as it runs. You can be roughly right about which business catches it and still do well, so it is more forgiving to own than a good company. This week it is hard drives so short that the money reached the company making the heads, Vietnam's power plan to 2030, and Japanese trucking rules pushing shippers to hand their whole distribution job to one contractor. In all 3 the money sits one step behind the obvious name, with the head inside the drive, the grid behind the factory and the warehouse behind the truck.
1
112
5 more I liked and could not fit, all credited inside the issue. πŸ”Ή Gulf Coast refiners with a coker buy Canadian heavy crude about $30 under WTI, because the world is short of the cokers that turn it into diesel. @kardamow πŸ”Ή The Atlantic basin cannot make enough diesel, and the Gulf Coast diesel crack printed $96.84 on 27 October while Singapore's sat just above $54. @STUARTTURLEY16 πŸ”Ή Every AI agent job gets a sealed computer of its own, which works out at 375,000 more server CPUs per million AI chips. Korea Invest Insights πŸ”Ή A humanoid robot needs 25 to 35 joints, and Tesla's 50,000-unit Optimus target alone would need about 750,000 reducers. Matthew, BitFinance πŸ”Ή Harmonic Drive, the main strain-wave gear supplier outside China, expects its robot part sales in fiscal 2030 to be 7 times fiscal 2025. AKS Research 9 writers did this work and I only picked between them, so follow them before me. Link in the comments.
1
70
Inside: how TDK's head margin went from 11.7% to 24.7% in one quarter, and the 1,000 trucking customers HAMAKYOREX has flagged as candidates to hand it the whole job. tradeideasflow.substack.com/…
33
πŸ’Ž MY FAVORITE STOCK PITCH FROM THE LAST 24H $IAM pitched by @ShawarmaCapital Iambic Therapeutics listed in October on a 36% response rate for its lead cancer pill. The confirmed rate, in the same filing, is 23%. Shawarma Capital read 5 offering documents, 13 versions of the trial registry and 29 insider filings. Every headline phrase "also has a second number sitting behind it, usually in the same filing". Quick translation. A response means the tumour shrank at least 30% on one scan. Confirmed means a second scan weeks later showed it held, and FDA labels use the confirmed count. Best find is in the confidential drafts, now public on EDGAR. They carry an earlier cut of the same trial, 27% confirmed in May. In 15 weeks the patient count grew by 12, best responses by 5, confirmed responses by 1. "The headline went up. The confirmed rate went down." The narrow reading is fair to the company: new patients had no time for a second scan yet. 4 responses were pending, and if all 4 confirm the rate is 30%, above May. More second numbers: β†’ the $16 IPO priced below the last 2 private rounds β†’ first half burn of $24.9M was $47.7M before partners paid ahead β†’ partners have paid about 2.8% of the ~$2.66B headline value of their deals β†’ "Nvidia-backed" is a 3.9% holding β†’ 32 months of free base rent on the first part of the new HQ, so rent starts mid-2029, after the cash runway. "Whoever funds 2029 pays it." Other side is just as documented. In HER2 breast cancer spread to the brain, after both T-DXd and tucatinib were already tried, 3 patients had confirmed brain responses and all are still on the drug. Nothing is approved in that setting. At the $11.64 close on Nov 5, enterprise value (market cap minus cash) was $142M against $409.4M of cash, down from $349M at the IPO price. So the overvaluation argument "is largely spent". It closed Tuesday at $14.78, about $291M of EV on the write-up's share count and cash (my math). Part 1 holds back a verdict. Part 2, out Monday, gives it: "I am bullish at $13.38." Shawarma Capital is long from $9.95.
$IAM's hidden metabolic bet: what the filings show, what they don't, and what it's worth Disclosure: I am long $IAM at an average of $9.95. Research, not advice. The short version β€’ Iambic told investors it works on metabolic disease, and its CEO repeated it on the record. That line was added to the IPO filing late, between the July and August drafts. β€’ The clue is GPCRs, the receptor family that GLP-1 and every other big obesity target belongs to. Iambic has a head of GPCR biology, and its audit chair sits on the board of a company with a $2.2B Novo Nordisk obesity deal. β€’ Peptides are a model capability, not a program. The prospectus never uses the word. β€’ The obesity pill race has moved on. The liver problem that killed Pfizer's pills has been solved by at least four groups. The open lanes are oral amylin, next-gen receptor targets and longer-lasting peptides. β€’ One typical early obesity deal pays about $80M to $110M upfront. That is a quarter to a third of Iambic's enterprise value. Nothing is priced in today. 1. Iambic said "metabolic". Then it said it again. The confidential IPO draft of 24 July 2026 does not mention metabolic disease. The next draft, on 28 August, adds this sentence, which survives unchanged into the final prospectus: "we are engaged in a number of discovery stage programs in indications, including oncology, metabolic disease and endocrinology, which we estimate represent an over $70 billion in aggregate global commercial opportunity." The same draft adds that Iambic has eight discovery programs, wholly owned and partnered, and expects up to 25 in 2027. It also says partnerships are expanding the platform to new target classes, "for example, G protein-coupled receptors". On 16 October the CEO, Tom Miller, was asked about moving beyond cancer. About the wholly owned pipeline, he said: "It includes metabolic disease. It includes endocrinology." (BioPharma Dive) The company's own documents do not all agree: β€’ The Enchant v3 page (21 September) lists the pipeline areas as oncology, neuroscience and inflammation and immunology. Metabolic is not listed. β€’ The risk factor on moving beyond cancer names neurology, gastrointestinal and inflammation only. β€’ There is no use-of-proceeds line for metabolic work and no metabolic row on the pipeline page. My read: something metabolic existed or was planned by late August, and Iambic chose to name it before the IPO. It has not said what. 2. Why GPCRs are the tell A GPCR (G protein-coupled receptor) is a switch on the surface of a cell. The big obesity targets are GPCRs: the GLP-1, GIP, glucagon, amylin and MC4R receptors. Lilly's new obesity pill, Foundayo, is a small molecule that flips the GLP-1 switch. What Iambic has: β€’ A GPCR team. An "Executive Director, Head of GPCR Biology" has appeared on Iambic's LinkedIn page since at least February 2025. β€’ GPCR agonist work. From March 2025 to March 2026 the pipeline page showed a partnered "GPCR target / allosteric agonist / neurological" program. That is very likely Lundbeck (my inference). It is the only disclosed work in which Iambic designs a pill that switches a GPCR on, which is the same job an oral GLP-1 does. It is in brain disease, not obesity. β€’ A boardroom view of the playbook. Audit chair Shalini Sharp has been a director of Septerna since January 2024. In May 2025 Septerna signed an obesity deal with Novo Nordisk worth up to about $2.2B, with more than $200M upfront and near-term. It covers oral small molecules on GPCR targets "including GLP-1, GIP, and glucagon receptors". None of this proves a program. It shows the skills, the people and the template are in the building. 3. Peptides: the capability is real, the program isn't β€’ Enchant v3 (September 2026) lists peptides as a new capability, citing "the success of GLP-1s". It publishes no peptide results. β€’ In NeuralPLexer3's paper, protein–peptide docking was its strongest category: 85.1% against 76.6% for AlphaFold-Multimer. That is 47 cases with overlapping uncertainty ranges, and AlphaFold 3 was not compared. β€’ The prospectus never uses the word "peptide". I found no peptide patent, no peptide program and no peptide job post in the live board or 65 archived ones. So "dark horse in peptides" is a stretch today. "Dark horse in oral metabolic pills" fits the evidence better. 4. Where the obesity market actually is The market is enormous: β€’ Lilly's tirzepatide (Mounjaro and Zepbound) sold about $36.5B in 2025 and $43.8B in the first nine months of 2026. β€’ Novo's semaglutide franchise sold about DKK 228B (roughly $35B) in 2025. Pills are coming, but the peptide pill is winning so far. In the first nine months of 2026 the Wegovy pill (oral semaglutide, a peptide) sold DKK 10.9B, roughly $1.7B. Foundayo (a small molecule) sold $281M. Part of that is timing: the Wegovy pill launched in January, Foundayo in April. Oral peptides are wasteful. The FDA label puts oral semaglutide's absorption at about 0.4% to 1%. The Wegovy pill is 25 mg a day against 2.4 mg a week injected. The liver problem is mostly solved. Pfizer stopped lotiglipron in 2023 and danuglipron in April 2025 over liver safety. Since then, orforglipron (Foundayo), Structure's aleniglipron, AstraZeneca's elecoglipron and MindRank's MDR-001 have reported no liver signal. MDR-001 was designed with AI property prediction and has been in Phase 3 in China since January 2026. "AI fixes the GLP-1 pill" is already a crowded story. What is still open: β€’ Weight loss. Pills take off about 11% to 15%, while injections reach 20% to 29% (retatrutide 28.7%). β€’ Oral amylin. Amylin is the hottest next-generation target. The only oral small-molecule amylin drug in human trials is Structure's ACCG-2671, in Phase 1 since December 2025. β€’ Longer-lasting peptides. Monthly shots and better half-lives. Half-life prediction is exactly what Enchant's first benchmark measured. That is where an AI chemistry platform with a GPCR group could matter. 5. What it could be worth What pharma paid upfront for early-stage (discovery or preclinical) obesity assets, 2023 to 2026: β€’ Novo – Lexicon (2025), preclinical, oral: $45M β€’ Lilly – Nimbus (Jan 2026), discovery, oral: $55M incl. near-term β€’ Merck – Hansoh (Dec 2024), preclinical, oral: $112M β€’ Novo – Valo (Jan 2025), discovery, AI: $190M incl. equity and near-term β€’ Novo – Septerna (May 2025), discovery, oral: >$200M incl. near-term β€’ Novo – Hengrui (Sep 2026), Phase 1-ready, oral: $300M The median across seven early deals is about $112M. Counting only clean upfronts (four deals), it is about $79M. For IAM: one such deal is $1.65 to $2.35 a share, about 25% to 36% of today's roughly $313M enterprise value. The market pays nothing for it today. The reality check: Structure Therapeutics. Structure has a Phase 3-ready oral GLP-1 and the only oral amylin pill in the clinic. Its enterprise value on 11 November was about $276M ($1.51B market value less $1.24B of cash), below Iambic's. The market is not handing out multiples for oral obesity pipelines. For Iambic, the value of a metabolic program arrives as partner cash, not as a re-rating. 6. What to watch β€’ Patents. International applications publish about 18 months after filing, so anything filed after about May 2025 is still invisible. A GPCR or incretin family appearing in 2027 would be the first hard proof. β€’ SEC comment letters. Once released, they may show whether the SEC asked about the August metabolic addition. β€’ The first 10-Q (around 30 November) and the J.P. Morgan conference (January): any named metabolic target. β€’ The job board. In vivo obesity pharmacology or GPCR metabolic roles. β€’ Bayer. The June 2026 deal's therapeutic area is still undisclosed. Bayer's focus is cardio-renal, oncology and women's health. Bottom line There is no named metabolic program, no peptide program and no metabolic partner. There is a late-added prospectus line, a CEO who said it twice in one breath, a GPCR team, a director who has seen a $2.2B Novo GPCR deal from the inside, and a deal market that pays about $80M to $110M upfront for exactly this stage. At about $313M of enterprise value, that is a free option on top of the HER2 drug, not the thesis. Size it that way. Long $IAM at $9.95. Not advice.
2
2
4
525
πŸ’Ž MY FAVORITE STOCK PITCH FROM THE LAST 24H $GLXZ pitched by The Stock Picker Evolution agreed to buy Galaxy Gaming for $3.20 a share in cash 2 years ago. The stock closed Monday at $1.54. Nevada approval never came, so in July Evolution walked away. The merger arbitrage traders, who held it only for the deal price, sold. Nanocap, OTC listing, no analyst covers it. What Galaxy owns is side bets for blackjack and baccarat: 21+3, Lucky Ladies, Perfect Pairs, EZ-Baccarat. Mostly it is a brand printed on the felt, and casinos pay a monthly fee for each bet on each table. Online casinos pay a share of what the games earn, 38% of revenue. By the company's count it owns 5 of the 7 most popular blackjack side bets in the world. Casinos tried copying them, without success. Players leave a game that does not "look right", and a side bet's house edge can be 10x blackjack's, so if the table earns even 5% less the saved licence fee is gone. During the 2 year wait the business got better: β†’ the 2021 Fortress loan at LIBOR + 7.75% refinanced with BMO at SOFR + 3.5%, interest down from $9.1M a year to about $3.1M β†’ recurring revenue from 82% to 99%, after Galaxy stopped selling one-off perpetual licences β†’ Evolution paid a $5.2M break fee, 12% of the market cap, and $4M of it goes to buying back shares and warrants Best homework in the write-up is on the biggest risk. Galaxy only distributes EZ-Baccarat, the deal ends September 2028, and the owner Talisman is a 2 person firm. Galaxy is Talisman's 3rd distributor in about 20 years. Talisman stayed around 10 years with the first and left Light & Wonder only when relations went bad. And leaving means every casino rips Galaxy's operating system and hardware off its tables. "Casinos hate operational downtime." Today it is 5.7x this year's estimated earnings, so $5.70 for each $1 of yearly profit. Light & Wonder is at 14.7x, Aristocrat 23.4x. On the write-up's 2028 numbers, 10x earnings is $2.52, +64% from Monday's close (the write-up used $1.60). And $3.20 "would not seem unreasonable to me: it is the same level at which Evolution had agreed to acquire the company."
1
1
2
466
The Stock Picker's full write-up, with the Talisman history, the refinancing and the 2028 math: πŸ“– hiddentenbagger.substack.com… I read every pitch like this at tradeideasflow.ai πŸ’ŽπŸŸ’
1
117
πŸ’Ž A SHAREHOLDER WROTE 50 PAGES TO CHECK IF THE STOCK IS TOO EXPENSIVE $HBFG.CN pitched by @TokStocks 3 years ago Happy Belly Food Group had 13 restaurants and about C$5M of revenue. Today more than 100, from Halifax to Lubbock, Texas, a C$34M revenue run-rate, and 686 committed franchise units, 460 of them for Heal Wellness alone. The catch is the price. At C$1.53 the market pays about C$250M for a business with roughly zero adjusted EBITDA over the last 12 months. About 9x sales, so 9 dollars for every dollar of yearly revenue, level with McDonald's. Keir Reynolds owns HBFG and still had a gut feeling the stock was expensive next to almost every listed restaurant company. So Keir went through every filing since 2024, the circular and more than a hundred news releases to test it. What came out of that: β†’ 48 cents of every Q2 2026 revenue dollar was stock-based compensation, pay in shares and options instead of cash β†’ money raised with convertible debentures (debt that can turn into shares) instead of selling new shares at a discount β†’ C$0.20 insider warrants, and C$2.00 performance awards that only vest at C$3 to C$10 β†’ bear, base and bull cases on a 10-year DCF built restaurant by restaurant, and how many restaurants it would take to get to C$5 a share Where it lands: on today's numbers it looks overvalued. Valued as a growth franchisor, with credit for the restaurants still to come, "the picture gets a lot more interesting." C$1.51 at Friday close. Q3 is out November 18, and the report has Keir's estimates for it.
1
1
247
The 50-page report is a download inside the write-up, with the peer table against McDonald's, Wingstop, CAVA and MTY, and the C$5 restaurant count: πŸ“– tokstocks.substack.com/p/hap… I read every pitch like this at tradeideasflow.ai πŸ’ŽπŸŸ’
1
95
πŸ’Ž MY FAVORITE STOCK PITCH FROM THE LAST 24H $CFE.CN pitched by @jaycurrie Cartier Silver reported 1,418.9 grams of silver equivalent per tonne of rock over 0.77m. Shares moved up $0.005. The market has a reason. 0.77m is a vein, the kind artisanal miners at Gonalbert have chased profitably for decades, and as Jay writes, "in modern mining terms chasing veins makes very little economic sense." So Jay went back to Cartier's 2023 releases: β†’ channel samples cut across the old underground workings. Every channel had silver, lead and zinc, 12 were over 100 g/t, a couple over 500, and the grades got better the deeper the samplers went β†’ a geophysics survey from surface, with an anomaly 800m by 500m around the veins going down at least 400m, which was just the depth limit of the survey Then the new release, about dewatering the old mine, mentions a 180 meter shaft at the Central Mine. "Huge by artisanal standards, a scratch from the perspective of modern mine design." Put that together and the question is whether the rich veins sit inside a big body of lower grade rock that still carries silver. If yes, Gonalbert could be an open pit, where you mine the whole body instead of following veins by hand. Dewatering is due by end of Q2 2027, then sampling and maybe drilling at depth, and a 43-101 resource estimate in 2027. C$0.115 at Friday close. The write-up priced it at C$0.105, a market cap of C$8.87M for the whole company. Jay owns shares. "The silver is definitely there."
1
1
1
168
Jay Currie's full piece, with the 2023 channel samples, the survey map and the shaft that changes the question: πŸ“– jaycurrie.substack.com/p/car… I read every pitch like this at tradeideasflow.ai πŸ’ŽπŸŸ’
1
73